Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up - European Society for Medical Oncology (ESMO)
The 2018 ESMO Clinical Practice Guidelines on hepatocellular carcinoma (HCC) are conceived to provide the standard approach to diagnosis and local and systemic treatment of HCC. New recommendations are provided regarding the locoregional management and the systemic treatment with lenvatinib, regorafenib, cabozantinib, ramucirumab and the anti-PD-1 antibodies (nivolumab and pembrolizumab) for advanced HCC. Also included are new diagnosis systems and treatment algorithms.
Read full Guideline